Metabolites (Apr 2023)

Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview

  • Ahmed Ismail Eatmann,
  • Esraa Hamouda,
  • Heba Hamouda,
  • Hossam Khaled Farouk,
  • Afnan W. M. Jobran,
  • Abdallah A. Omar,
  • Alyaa Khaled Madeeh,
  • Nada Mostafa Al-dardery,
  • Salma Elnoamany,
  • Eman Gamal Abd-Elnasser,
  • Abdullah Muhammed Koraiem,
  • Alhassan Ali Ahmed,
  • Mohamed Abouzid,
  • Marta Karaźniewicz-Łada

DOI
https://doi.org/10.3390/metabo13040543
Journal volume & issue
Vol. 13, no. 4
p. 543

Abstract

Read online

Glioblastoma is the most common malignant primary brain tumor in adults. Thalidomide is a vascular endothelial growth factor inhibitor that demonstrates antiangiogenic activity, and may provide additive or synergistic anti-tumor effects when co-administered with other antiangiogenic medications. This study is a comprehensive review that highlights the potential benefits of using thalidomide, in combination with other medications, to treat glioblastoma and its associated inflammatory conditions. Additionally, the review examines the mechanism of action of thalidomide in different types of tumors, which may be beneficial in treating glioblastoma. To our knowledge, a similar study has not been conducted. We found that thalidomide, when used in combination with other medications, has been shown to produce better outcomes in several conditions or symptoms, such as myelodysplastic syndromes, multiple myeloma, Crohn’s disease, colorectal cancer, renal failure carcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma. However, challenges may persist for newly diagnosed or previously treated patients, with moderate side effects being reported, particularly with the various mechanisms of action observed for thalidomide. Therefore, thalidomide, used alone, may not receive significant attention for use in treating glioblastoma in the future. Conducting further research by replicating current studies that show improved outcomes when thalidomide is combined with other medications, using larger sample sizes, different demographic groups and ethnicities, and implementing enhanced therapeutic protocol management, may benefit these patients. A meta-analysis of the combinations of thalidomide with other medications in treating glioblastoma is also needed to investigate its potential benefits further.

Keywords